APA (7th ed.) Citation

Mahajan, U. M., Oehrle, B., Goni, E., Strobel, O., Kaiser, J., Grützmann, R., . . . Mayerle, J. (2025). Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): A prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic study. The lancet. Gastroenterology & Hepatology, 10(7), . https://doi.org/10.1016/S2468-1253(25)00056-1

Chicago Style (17th ed.) Citation

Mahajan, Ujwal Mukund, et al. "Validation of Two Plasma Multimetabolite Signatures for Patients at Risk of or with Suspected Pancreatic Ductal Adenocarcinoma (METAPAC): A Prospective, Multicentre, Investigator-masked, Enrichment Design, Phase 4 Diagnostic Study." The Lancet. Gastroenterology & Hepatology 10, no. 7 (2025). https://doi.org/10.1016/S2468-1253(25)00056-1.

MLA (9th ed.) Citation

Mahajan, Ujwal Mukund, et al. "Validation of Two Plasma Multimetabolite Signatures for Patients at Risk of or with Suspected Pancreatic Ductal Adenocarcinoma (METAPAC): A Prospective, Multicentre, Investigator-masked, Enrichment Design, Phase 4 Diagnostic Study." The Lancet. Gastroenterology & Hepatology, vol. 10, no. 7, 2025, https://doi.org/10.1016/S2468-1253(25)00056-1.